Boehringer-Ingelheim to Present on Unique Monoclonal Antibodies at GTCbios Rediscovering Biomarkers Conference (July 23-24, San Diego, CA)
Summary
They have recently described a small-molecule antagonist of LFA-1, (BIRT 377) which inhibits LFA-1/ICAM-1 molecular interactions, LFA-1-dependent adhesion assays, antigen-induced proliferation of T-cells, and superantigen-induced production of IL-2 in vivo in mice.Additional topics to be covered include Biomarker Application in Oncology; Tools for Improving Measurement, Safety, and Validation; and Leveraging Upcoming Trends and Technologies.Their goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, as well as the financial community.Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, raniah@gtcbio.com ### Monrovia, CA, May 12, 2007 --( PR.com )-- Joseph R. Woska, Jr. is a Senior Scientist in the Department of Immunology and Inflammation at Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut will present on “Utilization of Unique Monoclonal Antibodies for the Detection of LFA-1 Antagonist Receptor Occupancy in Whole Blood” at Rediscovering Biomarkers: Detection, Development, and Validation Conference on July 23-24, 2007 in San Diego, CA.The b2 integrin LFA-1 (CD11a/CD18) is a leukocyte-specific adhesion molecule that mediates leukocyte extravasation, antigen presentation, and T-cell mediated cytolysis through its interaction with its counter-receptors, ICAM-1, ICAM-2 and ICAM-3.Additional topics to be covered include Biomarker Application in Oncology; Tools for Improving Measurement, Safety, and Validation; and Leveraging Upcoming Trends and Technologies.For more information including a detailed agenda, exhibitor opportunities and registration information visit http://www.gtcbio.com/conference/conferenceDetails.aspx?id=101ABOUT GTCbioGTCbio specializes in the organization and production conferences for the biomedical and biopharmaceutical industries.